SUBSCRIBE
SUBSCRIBE
News   Drug Development

Geron Corporation Presentations at the American Society of Clinical Oncology 2008 Annual Meeting

June 2, 2008 | 
1 min read

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced two presentations of its anti-cancer drug, GRN163L, given at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Clinical research Phase I Phase II Events
MORE ON THIS TOPIC
Novo Nordisk advertising flags and logo on facade
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
 · 
1 min read
 · 
Kate Goodwin
New York City, NY, USA - August 22, 2022: Pfizer world headquarters in New York City, USA. Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation.
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
December 12, 2024
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Cardiovascular disease
Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion
December 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Prostate cancer
Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data
December 12, 2024
 · 
3 min read
 · 
Tristan Manalac